UNICREDIT BANK/CALL/ELI LILLY & CO/1175/0.1/15.01.25 | Real-time BOERSE MUENCHEN 11:40:43 2024-05-24 EDT | ||
| 1.09 EUR | -9.17% |
|
| Current month | +25.00% | ||
| 1 month | +53.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 1.09 | -9.17% |
| 24-05-23 | 1.2 | +18.81% |
| 24-05-22 | 1.01 | +3.06% |
| 24-05-21 | 0.98 | +20.99% |
| 24-05-20 | 0.81 | +9.46% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 11:40 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBQ |
| ISIN | DE000HD4LBQ0 |
| Date issued | 2024-04-12 |
| Strike | 1,175 $ |
| Maturity | 2025-01-15 (236 Days) |
| Parity | 10 : 1 |
| Emission price | 1.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.2 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.04 € |
| Spread % | 3.60% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
808.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.24%
- Stock Market
- Warrants
- Warrant
